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Introduction
The vioprolides A-D 1-4 comprise a small group of depsipeptides with a range of biological activities that were isolated from the myxobacterium Cystobacter violaceus strain Cb vi35. 1 Of the four natural products, vioprolide D 4 was found to be the most active against a variety of fungi and yeasts yet it was the least toxic towards mammalian cells. 1 In a separate study, vioprolide A 1 was found to exhibit a three-fold synergistic effect on the murine type 1 interferon signalling pathway and modulated the NF-κB pathway in cell-based assays thereby showing anti-inflammatory properties. 2 However, the mechanisms of action of the vioprolides are not known. The synthesis of the vioprolides and analogues is therefore of interest in order to provide more material for further biological investigations. We here describe studies that have resulted in the total synthesis of macrocyclic precursors of vioprolide D. 3 A synthesis of the azetidinyl-thiazolinyl fragment of vioprolides A and C is the only other contribution to vioprolide synthesis published to date. 4 The vioprolides are depsipeptides that comprise eight amino acids, or amino acid derived fragments, together with an (S)-glyceric acid unit. The variable positions are occupied by L-homoproline or L-proline and by (2S,4R)-4-methyl-azetidinecarboxylic acid or L-proline, see Fig. 1 . Atropisomers have been detected across the N-methylvaline amide bond. A D-leucine is present in all vioprolides. 1 It was decided to study a synthesis of vioprolide D 4 first in order to enable a strategy to be developed without the need for the synthesis of the 4-methylazetidinecarboxylic acid. It was envisaged that the same approach could be applied to other members of the series. The introduction of the (E)-dehydrobutyrine and the adjacent thiazoline residue was recognised as the most challenging aspect of the synthesis since steric interactions tend to make (E)-dehydrobutyrines less stable than their (Z)-isomers. Indeed several anti-elimination processes are available for the synthesis of (Z)-dehydrobutyrines from threonine 5 whereas just one procedure involving a syn-dehydration process, 6 is known for the direct synthesis of esters of (E)-dehydrobutyrines from threonine. In addition two methods have been reported for the synthesis of esters of (E)-dehydrobutyrines by anti-elimination from allothreonine. 5a,7 Procedures for the introduction of cysteine-derived thiazolines into depsipeptides include the DAST-mediated dehydration of serine-derived thioamides 8 and a biomimetic, one-pot, deprotectiondehydration of S-trityl derivatives of cysteine. 9 
Results and discussion
Preliminary studies on the assembly of the (E)dehydrobutyrine-thiazoline component
The epimerisation of amino acid residues adjacent to thiazolines in peptide derivatives is well known 8, 9 and so it was decided to introduce the (E)-dehydrobutyrine before the thiazoline. However, early studies had shown that attempts to convert the (E)-dehydrobutyrine containing tripeptide derivative 5 into the thiazoline 6 by one-pot S-deprotection and dehydration following the literature procedure 9 using triphenylphosphine oxide and triflic anhydride gave complex mixtures of products possibly formed by reaction of the intermediate thiol with the double-bond of the dehydrobutyrine, see Scheme 1. 3 It was therefore decided to ascertain whether the introduction of thiazolines by dehydration of serine-derived thioamides was more compatible with the presence of an adjacent (E)-dehydrobutyrine. 3 The tert-butyldimethylsilyl ether 7 of L-threonine allyl ester was coupled with Fmoc-protected serine to give the protected dipeptide 8 that was converted into the amino dipeptide 10 via the bis-silyl ether 9. Following the literature procedure for the preparation of the Boc-analogue, 8, 10 Fmoc-protected proline was converted into its amide 12 using 2-amino-4-nitroaniline and the amide taken through to the thioamide 13 using phosphorus pentasulfide. Diazotisation gave the benzotriazole 14 that was used to acylate the amino dipeptide 10 to give the thioamide 15 after removal of the Fmoc-protecting group. Coupling the amine 15 with Boc-protected D-leucine then gave the fully protected tetrapeptide 16. Selective removal of the tert-butyldimethylsilyl group in the presence of the tri-isopropylsilyl group proved difficult and so both silyl groups were removed using tetra-n-butylammonium fluoride and the primary hydroxyl group of the serine selectively resilylated to give the tetrapeptide derivative 17, see Scheme 2.
Dehydration of the tetrapeptide derivative 17 using 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide (EDC) and copper(II) chloride as a catalyst via a syn-dehydration following the literature procedure, 6 gave the (E)-dehydrobutyrine 18 containing about 5% of its (Z)-isomer, see Scheme 2. The (E)-geometry was assigned to the major product from this reaction by analogy with the literature and by comparison with the (Z)isomer 21 prepared by dehydration of the threonine containing peptide 17 using DAST 5a [δ H CH 3 CHv; 18, 1.98; 21, 1.72] .
Desilylation of the protected (E)-dehydrobutyrine containing tetrapeptide 18 gave the primary alcohol 19. Dehydration Scheme 1 Unsuccessful introduction of the thiazoline in the presence of an (E)-dehydrobutyrine. Scheme 2 Synthesis of the (E)-dehydrobutyrine-thiazoline-L-pro-D-leu fragment 20 of vioprolide D. Reagents and conditions: i, Fmoc-L-ser, HATU, HOBt, i Pr 2 NEt, DMF, rt, 16 h (97%); ii, TIPSOTf, 2,6-lutidine (2,6lut.) , DCM, rt, 16 h (56%); iii, piperidine ( pip.), DMF, rt, 16 h (89%); iv, 2-amino-4-nitroaniline, i BuOC(O)Cl, N-methyl-morpholine (NMM), THF, −20°C to rt, 16 h (79%); v, P 4 S 10 , Na 2 CO 3 , THF, 0°C, 30 min (71%); vi, NaNO 2 , glac. AcOH, H 2 O, 0°C, 30 min (86%); vii, (a) 10, 14, THF, rt, 6 h (66%) (b) pip., DMF, rt, 16 h (66%); viii, Boc-D-leu, HATU, HOBt, i Pr 2 NEt, DMF, rt, 16 h (85%); ix, (a) TBAF, THF, rt, 16 h (45%) (b) TIPSCl, imid., THF, rt, 48 h (68%); x, EDC, CuCl 2 (cat.), tol., 80°C, 30 min (65%); xi, TBAF, THF, rt, 16 h (62%); xii, DAST, −15°C, 1 h (75%); xiii, DAST, py., 0°C, 2 h (31%). using DAST then gave the required thiazoline 20 in which the (E)-dehydrobutyrine was still intact, Scheme 2. The 1 H NMR spectrum of the thiazoline 20 in DMSO-d 6 at room temperature was complicated by the presence of two rotamers due to the Boc-group, ratio ca. 80 : 20. On repeating the NMR spectrum at 100°C, the peaks of the rotamers coalesced, but they separated out as the solution was cooled back to room temperature. Rotamers were also observed for all the Fmoc-protected amines, e.g. the serine derivatives 8 and 9, prepared during the course of this work and caused broadening of the 1 H NMR spectra of these compounds at room temperature.
Yields were not optimised during these preliminary investigations but the assigned structures were consistent with the results of later investigations. The successful synthesis of the modified tetrapeptide 20 that contained both the (E)-dehydrobutyrine and the adjacent thiazoline led to the design of the first approach for a convergent synthesis of vioprolide D 4.
The first approach to vioprolide D; synthesis and chemistry of the modified pentapeptide 22
Based on the preliminary investigations, 3 the synthesis of vioprolide D 4 from the modified pentapeptide 22 and the tripeptide ester 23 shown in Fig. 2 was conceived. At the onset of the work the conversion of allyl esters of (Z)-dehydrobutyrines into proline-derived amides was known, 11 and so the formation of the proline to (E)-dehydrobutyrine peptide bond was identified as a suitable assembly point since it would avoid α-epimerisation of the acidic component. Macrocyclisation by amide formation between the glyceric acid residue and the L-alanine would then provide a convergent synthesis. 12, 13 The thiazoline would have to be introduced as late as possible in the synthesis to avoid epimerisation and so the hydroxyl groups in fragment 23 would need to be protected. The 2,2,2trichloroethoxycarbonyl (Troc) group was selected for this purpose since conditions were known for its reductive removal in the presence of thiazolines. 8d,14 It was intended to use the allyl ester of the glyceric acid since its palladium(0) catalysed removal should be compatible with the N-methylvaline derived ester present in fragment 23, see Fig. 2 .
A synthesis of the modified pentapeptide 22 is outlined in Scheme 3. This is based on the chemistry outlined in Scheme 2 but includes improvements. In particular it was found not to be necessary to protect the hydroxyl group of the threonine during the synthesis and the tert-butyldimethylsilyl protecting group was preferred for the hydroxyl group of the serine. L-Threonine 24 was converted into its allyl ester that was coupled with Fmoc-protected serine to provide the dipeptide 25. This was silylated to give the tert-butyldimethylsilyl ether 26. Following deprotection, the amino-dipeptide 27 was acylated using the benzotriazole 14 to give the thioamide 28 that was deprotected to give the prolinyl peptide 29. Acylation using Fmoc-protected D-leucine gave the tetrapeptide analogue Scheme 3 Synthesis of the (E)-dehydrobutyrine 22. Reagents and conditions: i, (a) allyl alcohol, TsOH, tol., 110°C, 16 h (b) Fmoc-L-ser, HATU, HOBt, i Pr 2 NEt, 0°C to rt, 16 h (74%); ii, TBSCl, imid., THF, rt, 16 h (79%); iii, pip., THF, rt, 3.5 h (68%); iv, 14, THF, 0°C to rt, 16 h (98%); v, pip., THF, rt, 4.75 h (95%); vi, Fmoc-D-leu, HATU, HOBt, rt, 16 h (75%); vii, Et 3 N, DCM, EDC·HCl, HOBt, rt, 16 h (85%); viii, H 2 , Pd/C, EtOAc, rt, 16 h (96%); ix, HATU, HOBt, DCM, rt, 16 h (68%); x, EDC, CuCl 2 (cat.), tol., 80°C, 2.5 h (53%); xi, Et 3 N, MsCl, DCM, 0°C to rt, 30 m in (58%) .
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Org. Biomol. Chem., 2018, 00, 1-26 | 3 30 but attempts to remove the Fmoc-protecting group led to mixtures of products. It appeared that the free amine derived from the D-leucine had reacted with the thioamide, perhaps to form an amidine, but no product was isolated or characterised (see Experimental). However, the N-protected dipeptide 34 was prepared from Boc-protected L-alanine 31 and the benzyl ester 32 of D-leucine, followed by hydrogenolysis of the benzyl ester 33, and was coupled with the tripeptide derivative 29 to give the modified pentapeptide 35. Dehydration with EDC and copper(II) chloride then gave the required (E)-dehydrobutyrine 22, see Scheme 3.
Structures were assigned to the products in Scheme 3 by analogy with the literature and from spectroscopic data. Intermediates with Fmoc-protected prolines, e.g. the thioamide 28, were found to have broadened 1 H NMR spectra attributed to the presence of rotamers, but following removal of the Fmoc-group the resulting amines, in this case intermediate 29, had more distinct 1 H NMR spectra. For comparison, the threonine-derived pentapeptide 35 was dehydrated using mesyl chloride and triethylamine, to give the (Z)-dehydrobutyrine 36. As before, the (E)-and (Z)-dehydrobutyrines 22 and 36 were distinguishable by NMR [δ H CH 3 CHv; 22, 1.99; 36, 1.84] .
This synthesis had provided the required (E)-dehydrobutyrine-containing intermediate 22 but the crucial dehydration step was capricious with yields of 20-50% typically obtained and the (E) : (Z)-selectivity (ca. 80 : 20) appeared to be less than had been observed in the earlier study. Moreover, attempts to convert the allyl ester 22 into the corresponding acid by palladium(0) catalysed deallylation, 15 gave only discoloured mixtures of products and the modified hexapeptide 37 was not isolated from attempts to couple the crude deallylated product with methyl L-prolinate, see Scheme 3.
As this work was being carried out, a paper was published that reported difficulties in converting an ester of an (E)-dehydrobutyrine into an amide because of isomerisation into the more stable (Z)-dehydrobutyrine. 16 It was therefore decided to evaluate the viability of the proposed use of the (E)-dehydrobutyrine 22 in the assembly of macrocyclic precursors using simpler (E)-dehydrobutyrine containing peptides. L-Threonine 24 was taken through to the dipeptide 38 11b that was monosilylated to give the tert-butyldimethylsilyl ether 39. Boc-protected serine was used in this case to avoid N-deprotection in the dehydration step. Dehydration using EDC and copper(II) chloride was now efficient and gave a good yield of the (E)-dehydrobutyrine 40, see Scheme 4. However, the attempted conversion of this dipeptide into the (E)-dehydrobutyrine containing tripeptide 42 by palladium catalysed deallylation and coupling the crude product with methyl L-prolinate was discouraging. Only low yields of impure products were isolated that could not be properly characterised. The threonine containing dipeptide 39 was taken through the deallylation and coupling steps to give the protected tripeptide 41 albeit these reactions were not optimised, see Scheme 4. However, the attempted dehydration under the EDC-copper(I) chloride conditions of the threonine containing tripeptide 41 to give the (E)-dehydrobutyrine 42 was unsuccessful.
The EDC-copper(II) chloride procedure for the introduction of the (E)-dehydrobutyrine into advanced intermediates was proving troublesome. Moreover, the conversion of the (E)-dehydrobutyrine containing esters 22 and 40 into the corresponding prolinyl amides 37 and 42 had not been achieved. It was concluded that assembly of the vioprolides by formation of the (E)-dehydrobutyrine-proline peptide bond, as proposed in Fig. 2 , was unlikely to be successful. 16 The first approach to vioprolide D; synthesis and chemistry of modified peptides analogous to the proposed intermediate 23
In parallel with this work, studies were carried out on the synthesis and chemistry of the glyceric acid containing fragment 23. The selective mono-esterification of the allyl ester of (S)-glyceric acid using an N-protected N-methyl-L-valine was identified as the potentially difficult step in this synthesis. L-Serine 43 was diazotised following a minor modification of the literature procedure, 17 and esterification of the resulting (S)-glyceric acid gave the allyl ester 44, 17 see Scheme 5. This was taken through into the Troc-protected ester 45 but this ester was found to be unstable during chromatography with respect to cyclisation to the carbonate 46, and attempts to carry out regioselective mono-esterification of alcohol 45 using a protected N-methyl valine 18 were unsuccessful. The direct esterification of the dihydroxy ester 44 using Boc-protected N-methylvaline 47 was therefore investigated. Indeed with an excess of the dihydroxyester to minimise bis-esterification, the DCC-DMAP mediated esterification gave an acceptable yield (62%) of the required ester 48 together with its regioisomer 49 (22%) and a minor product provisionally identified as the bisester 50 (10%). The structures of these separable products were assigned from spectroscopic data. Further optimisation of this esterification was not studied at this stage. The hydroxy ester 48 was protected 8d,14 as its Troc-derivative 51 and, after removal of the Boc-group, the N-methylamine 52 was coupled with Boc-L-threonine to give the dipeptidyl ester 53. Using HATU, this coupling was rather slow, 3.5 days, but was efficient, 85%. To complete the synthesis of a fragment that corresponded to the tripeptide derivative 23, Fig. 2 , it remained to remove the Boc-group and to couple the resulting amine with a protected proline. Free amines of dipeptidyl esters with N-methylamino acid components can undergo cyclisation to diketopiperazines competitively with N-acylation. 19 However, in the present case, removal of the Boc-group from the dipeptide 53 and coupling with Boc-protected L-proline using a mixed anhydride procedure gave the required tripeptidyl glycerate 54 in an acceptable yield of 77%, see Scheme 5.
The tripeptidyl glycerate 54 is the Boc-analogue of the targetted intermediate 23. Of interest was the relatively efficient construction of the threonine-proline peptide bond in this tripeptide. The formation of this bond may therefore be useful for vioprolide assembly. However, it remained to establish the viability of the other proposed assembly step, i.e. formation of the peptide bond between the glyceric acid moiety and a complementary amino peptide as shown in Fig. 2 . Palladium(0) catalysed deallylation of the dipeptidyl glyceride 53 was not very clean although a sample of the hydroxyacid 55 was isolated after chromatography. However, attempts to couple this acid with the amino dipeptide 60, prepared by removal of the Boc-group from the previously prepared intermediate 33, gave rise to complex mixtures of products from which only very low yields of the required amide 56 could be isolated. The amide 56 was identified from 1 H and 13 C NMR that showed that both fragments were present including the 2,2,2-trichloroethoxy carbonate, and the low resolution MS confirmed the molecular weight. However, this reaction was very capricious and difficult to repeat. To avoid participation of the threonine hydroxyl group, ester 53 was converted into its bis-Troc-derivative 57. Deallylation now gave the acid 58 in which both of the hydroxyl groups were protected, but attempted coupling of this with the amino-dipeptide 60 surprisingly 20, 21 gave the tetrapeptide 59 that had lost the glyceric acid moiety, see Scheme 6. The structure of tetrapeptide 59 was assigned using spectroscopic data.
The formation of the tetrapeptide 59 may have involved participation of the cyclic intermediate 61 derived from the activated acid and the adjacent Troc-protected alcohol. 22 Such an intermediate should be prone to enolisation since its enolate 62 would be stabilised by aromaticity. However, this enolate could also fragment with loss of the carboxylate 63. The corresponding acid would then be able to couple with the amine 60, 
Org. Biomol. Chem., 2018, 00, 1-26 | 5 to give the observed tetrapeptide 59, see Fig. 3 . Different reaction conditions might avoid this side-reaction, but it was decided instead to study alternative glycerate protection. Reductive removal of the Troc-group from the glyceride 53 gave the dihydroxydipeptide glyceride 64 that was converted into the bis-acetate 65. Following palladium(0) catalysed deallylation, the resulting acid 66 was coupled with the peptide ester 60 to give the required glyceric peptide 67 in a good yield with no side products formed by unwanted participation of the acetates, see Scheme 7. Triethylsilyl protection of the diol 64 was also investigated but some cleavage of the triethylsilyl ethers was observed during the deallylation and coupling steps, and so acetate protection was preferred at this stage.
Revised strategy for synthesis of vioprolide D
At this point it was decided to revise the strategy for a synthesis of vioprolide D 4, see Fig. 4 . The introduction of (E)dehydrobutyrines into advanced intermediates by syn-dehydration of threonine-derived peptides was proving difficult even though good yields and stereoselectivities had been observed for simpler substrates. However, a procedure for the introduc-tion of (E)-dehydrobutyrines into peptides based on the oxidative elimination of selenides prepared from allo-threonines with inversion of configuration, is well known. 23 Indeed an (E)dehydrobutyrine has been introduced into a complex depsipeptide using this procedure. 24 A synthesis of vioprolide D 4 using a selenoxide elimination for introduction of the (E)dehydrobutyrine was therefore considered (Fig. 4 ).
In this revised approach, the two components were to be the modified hexapeptide 68 and the dipeptide glyceride 65. Both of the proposed assembly steps have precedents in the studies outlined in Schemes 5 and 7. Protection of the glycerate as its bis-acetate for the peptide bond formation involving the glyceric acid had been established although it was realised that difficulties might arise in saponification of these acetates later in the synthesis in the presence of the glycerate. At the onset of the work, it was not clear that oxidative removal of the selenide would be compatible with the presence of a thioamide, or with the thiazoline, if this were to be introduced first. For these reasons, it was decided to use phenylselenides prepared from threonine for preliminary studies to evaluate the overall strategy even though these would lead to (Z)-dehydrobutyrines. There are precedents for isomerisation of (Z)dehydrobutyrines into (E)-dehydrobutyrines by benzeneselenol addition-oxidative elimination 23 and so, if necessary, it might be possible to effect such an isomerisation later in the synthesis.
The 3-phenylselanylbutanoic acid 71 was prepared from Boc-protected threonine 69 via the oxetane 70 following the literature. 25, 26 Esterification gave the methyl ester 72 that was deprotected and the free amine coupled with O-TBS-N-Boc-protected serine to give the protected dipeptide 73. Removal of the Boc-group and coupling with the benzotriazole 14 gave the thioamide 74 after removal of the Fmoc-group. This was coupled with the dipeptide acid 34 to give the pentapeptide derivative 75. Surprisingly, saponification of the methyl ester and coupling the resulting acid with methyl L-prolinate gave the (Z)-dehydrobutyrine 76 by loss of benzeneselenol. It may have been possible to tweak the sequence to avoid this elimination, but instead the 3-phenylselanylbutanoic acid 71 was coupled with methyl L-prolinate to give the dipeptide 77. This was taken through to the tripeptide 78 by removal of the Boc- 
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This journal is © The Royal Society of Chemistry 2018 protecting group and coupling the resulting free amine with O-TBS-N-Boc-protected serine. Cleavage of the Boc-group, in this case using trimethylsilyl triflate and 2,6-lutidine to avoid competing loss of the TBS-group, and coupling the amine with the benzotriazole 14 gave the thioamide 79 after removal of the Fmoc-group. The thioamide 79 was then coupled with the dipeptide acid 34 to give the hexapeptide 80, see Scheme 8.
Structures were assigned to the products in Scheme 8 from spectroscopic data. Oxidative elimination of the phenylselanyl group from the selenide 80 gave the same dehydrobutyrine that had been isolated from the methyl ester 75, vide infra. This was therefore identified as the (Z)-isomer 76 (CH 3 CH, δ 1.71) formed via an apparently syn-selective, E1cb elimination process.
Synthesis of macrocyclic precursors of (Z)-iso-vioprolides
Careful saponification of the methyl ester 80 gave the carboxylic acid 81. This was coupled with the amine 82 that had been prepared by selective deprotection of the glyceride 65 to give the octapeptidyl glyceride 83 in an excellent yield (84%). Palladium(0) catalysed cleavage of the allyl ester and careful acid catalysed removal of the Boc-group then gave the aminoacid that was cyclised to give the macrocyclic intermediate 84 in a yield of 50% over the three steps. At this point attempts were made to remove the acetate protecting groups. In the event, removal of both of the acetates was not achieved. However a careful saponification 27 appeared to remove one of the acetates and gave a modest, 40%, yield of a product that was provisionally identified as the alcohol 85, see Scheme 9.
Two variations of the synthesis of the macrocyclic compound 84 were investigated. The Troc-protected glyceride 53 was deprotected to give the free amine 86 that was coupled with the acid 81 to give the octapeptidyl glyceride 87. Removal of the Troc-group gave the corresponding diol that was esterified using acetic anhydride to give the advanced intermediate 83, see Scheme 10. This synthesis was useful in that it confirmed that coupling of the dipeptidyl glyceride 86, in which 
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In a second variation of the synthesis of the macrocycle 84, the Boc-group of the hexapeptide 80 was replaced by an allocgroup 28 to give the carbamate 88, see Scheme 11. This was to avoid the acid-catalysed removal of the Boc-group at the end of the synthesis. Earlier this had been complicated by competing loss of the tert-butyldimethyl silyl group. After saponification of the ester moiety in the carbamate 88, the resulting acid was coupled with the amine 82 to give the octapeptidyl glyceride 89. This was now taken through to the macrocycle 84 in two steps rather than three.
Reversing the assembly steps was also briefly investigated. The acid 81 prepared by saponification of the methyl ester 80 was esterified using 2,2,2-trichlorethanol to give the trichloroethyl ester 90. 29 Removal of the Boc-group and coupling with the acid 66 now gave the amide 91 that on treatment with activated zinc was converted into the acid 92 without any competing loss of the acetates or cleavage of the glycerate. However, on attempted removal of the Boc-group from the threonine residue and macrocyclisation, the only product that could be isolated was the diketopiperazine 93, see Scheme 12. The formation of diketopiperazines from esters of N-alkylated dipeptides is well known 19 although it hadn't been a problem in the intermolecular coupling of the acid 81 and amine 82. This approach to the macrocycle 84 was not studied any further.
Synthesis of macrocyclic precursors of vioprolides
A synthesis of the hexapeptide 68 required for a synthesis of vioprolide D is outlined in Scheme 13. This follows the chemistry developed during the synthesis of its epimer 80 outlined in Scheme 8. In this case, Boc-protected allothreonine 94 was cyclised to give the oxetane 95 30 that on treatment with benzeneselenol gave the selenide 96 with inversion of configuration. Coupling with methyl L-prolinate gave the dipeptide 97 that was converted into the tripeptide 98 by acid catalysed deprotection and coupling with O-TBS-N-Boc-serine. Deprotection using trimethylsilyl triflate and 2,6-lutidine gave the amine 99 that was acylated using the benzotriazole 14 to give the tetrapeptide 100 after removal of the Fmoc-group using piperidine. The tetrapeptide 100 was then coupled with the acid 34 to give the required hexapeptide 68, see Scheme 13. During the synthetic approach to iso-vioprolides, see Scheme 9, it had been found that removal of the acetate from the threonine hydroxyl group was more difficult than selective saponification of the acetate of the glyceric acid, as exemplified by the conversion of bis-acetate 84 into the mono-acetate 85. Protection of the 2-hydroxyl group of the glyceric acid, e.g. as its acetate, was important for formation of the peptide bond of the glycerate, but it was not clear that protection of the hydroxyl group of the threonine was necessary for this step. To clarify this point, the glycerate 48 was acetylated and then deprotected to give the amino-bis-ester 101. This was coupled with N-Boc-L-threonine to give the dipeptidyl glyceride 102. After removal of the Boc-group, coupling the resulting amine with Boc-protected proline gave the tripeptidyl glyceride 103 as expected from the synthesis of the octapeptidyl glyceride 87. However, it was also confirmed that the remote hydroxyl group of the threonine did not interfere with peptide formation involving the glycerate now that the 2-hydroxy group of the glycerate is protected as its acetate and not as a Troc-carbonate. Thus following palladium (0) catalysed cleavage of the allyl ester 102, peptide bond formation using the amino dipeptide 60 gave the glyceric acid amide 104, see Scheme 14.
To assemble a macrocyclic precursor of vioprolide D 4, the acid 105 was prepared by saponification of the hexapeptidyl ester 68, and was coupled with the amine 106, that had been prepared from the monoacetylated dipeptidyl glycerate 102, to give the octapeptidyl glycerate 107. Stepwise removal of the allyl ester and the Boc-group followed by macrolactamisation then gave the macrocycle 108 as shown in Scheme 15.
The structures shown were assigned to the compounds in Scheme 15 from their spectroscopic data. The methyl group of the acetate in the macrocycle 108 was at δ 2.10 in its 1 H NMR spectrum. In the macrocyclic bis-acetate 84, the two acetate methyl groups were at δ 2.03 and at 2.12. In the mono-acetate prepared by selective saponification, the remaining acetate methyl group was at δ 2.04 with no acetate methyl singlet present at or near to δ 2.12. This is consistent with the selective saponification of the acetate of the glycerate and confirms the monoacetate prepared by saponification as that shown in structure 85 with the remaining acetate being that on the threonine.
The modified depsipeptide 108 would appear to be a promising intermediate for a synthesis of the (E)-dehydrobutyrinecontaining vioprolide D 4. However, it was decided to check the viability of the proposed oxidative and dehydration reactions using substrates prepared from the earlier intermediates 68 and 80 before using valuable macrocyclic intermediates.
Preliminary studies of the oxidative elimination
Oxidative elimination of the phenylselanyl moiety from the hexapeptide 80 gave the (Z)-dehydrobutyrine 76, Scheme 16. The (Z)-configuration of the double-bond in this dehydrobutyrine was assigned on the basis of syn-elimination of selen- Removal of the tert-butyldimethylsilyl group from the threonine-derived hexapeptide 80 gave the free alcohol 109 but attempts to take this through to the corresponding (Z)-dehydrobutyrine-thiazoline by DAST-mediated dehydration followed by oxidative elimination gave products that were difficult to characterise conclusively because of the presence of rotamers although (Z)-alkenes seemed to be present and good yields (75-80%) were obtained (see Experimental).
However, the oxidative elimination of the phenylselanyl group from the epimeric selenide 68 did not give the expected (E)-dehydrobutyrine. Instead the terminal alkene 111 was obtained, see Scheme 16. Similarly the alcohol 110 prepared from the hexapeptide 68 gave what appeared to be the terminal alkene containing thiazoline after dehydration and oxidative elimination although again the products were not properly characterised because of the presence of rotamers.
The formation of the terminal alkene 111 on oxidative elimination of the selenide 68 was unexpected and is perhaps indicative of just how sterically hindered (E)-double-bonds are in this system when the vinylic methyl group is proximate to a proline residue.
The but-3-enyl containing modified peptide 111 appeared to be predominantly a single epimer. A direct selenoxide elimination to give the terminal alkene would have retained the configuration at C2 of the but-3-enyl residue but this configuration cannot be assumed if the product 111 had been formed by isomerisation of an initially conjugated intermediate and so is not defined in structure 111. The oxidative elimination was also attempted on the macrocycle 84 (derived from threonine) and gave a (Z)-dehydrobutyrine as expected from a synelimination process (CH 3 CHv, δ 1.77). However, the product was shown by 13 C NMR and MS to be the amide 112 not the expected thioamide perhaps because of adventitious oxidation due to the excess of oxidant that was used in this one-off, very small scale, reaction, see Scheme 17.
Summary and conclusions
This paper reports progress towards a total synthesis of vioprolide D 4. The modified depsipeptide 108 would appear to be a promising advanced intermediate since removal of the acetate in the presence of the glycerate is precedented in the conver- sion of the bis-acetate 84 into the mono-acetate 85. The diol derived from the acetate 108 could then be protected as its bis-Troc-carbonate and the introduction of the thiazoline and dehydrobutyrine moieties would be studied. The formation of the terminal alkene 111 rather than the conjugated (Z)-dehydrobutyrine on oxidative elimination from the intermediate 68 was unexpected since there are precedents for the introduction of (E)-dehydrobutyrines into peptides by selenoxide elimination. 23 The oxidative elimination of selenides to give terminal alkenes can be slow, often being facilitated in synthesis by the use of aryl selenides with electron withdrawing groups in the aromatic ring. Conversely, the 2-acylamino residue in the selenide 68 may be slowing down selenoxide elimination to the conjugated but-2-enoate, although this doesn't appear to be a problem for its epimer 80. It may be that the adjacent proline residue is providing more steric hindrance towards (E)-dehydrobutyrine formation than is present in the other (E)-dehydrobutyrine-containing peptides that have been prepared by selenoxide elimination to date. 23 Perhaps this proline is preventing the selenoxides derived from selenide 68 from adopting the preferred conformation for elimination in which H2 would be aligned with the π-orbitals of the carbonyl group as well as being accessible for the periplanar, syn-elimination process. However, macrocyclic intermediates derived from allothreonine may have very different conformations from those of the simpler intermediate 68, and so could provide access to (E)-dehydrobutyrines on selenoxide elimination. This possibility is well worth investigation.
The iso-vioprolides with (Z)-dehydrobutyrines should be much more accessible than their (E)-isomers, cf. the isolation of the (Z)-dehydrobutyrines 76 and 112. The biological activities of these vioprolide analogues are of interest in their own right. Moreover, several procedures can be envisaged for the conversion of (Z)-dehydrobutyrine-containing vioprolides into their (E)-isomers in addition to the known benzeneselenol additionoxidative elimination sequence. 23 The hexapeptides and dipeptide glycerides, e.g. 68 and 102, are available on multigramme scales and, although the assembly steps have not been optimised, the macrocycles reported here should be relatively accessible for further work. The observations made on the effect of the Troc-carbonate of the 2-hydroxyl group of the glycerate on attempted amide formation are interesting and must be due to fairly subtle effects since the corresponding acetate did not interfere and analogous coupled products have been obtained in similar systems. 21 Finally, perhaps it is worth concluding that, because of their biological activities, the vioprolides remain challenging yet important targets for synthesis. It is hoped that further work will be carried out in this area, not only on syntheses of the natural products themselves, but also of analogues for biological evaluation. We are unable to continue with our studies on vioprolide synthesis but we very much hope that the investigations reported in this paper will help to encourage further work in this potentially important area.
Experimental

General experimental details
Flash column chromatography was performed using Merck silica gel (60H; 40-60 μ, 230-240 mesh). Light petroleum refers to the fraction boiling between 40 and 60°C and was redistilled. Tetrahydrofuran was dried over sodium-benzophenone and was distilled under nitrogen. Dichloromethane was dried over CaH 2 and was distilled. Ether refers to diethyl ether. Reactions under non-aqueous conditions were carried out under an atmosphere of nitrogen or argon.
Mass spectra used electron impact ionisation (EI + ), chemical ionisation using ammonia (CI + ), electrospray ionisation in the positive mode (ES + ), atmospheric pressure chemical ionisation in the positive mode (APCI + ) and time of flight MS with electrospray ionisation (TOF ES + ). Low resolution and high resolution mass spectra were recorded using a Micromass Trio 200 and a Kratos Concept IS spectrometer, respectively. Characteristic groups of peaks were observed in mass spectra for compounds containing selenium and chlorine atoms. Accurate mass data correspond to compounds with the isotopes 80 Se and 35 Cl. Infra-red spectra were measured using a Genesis FTIR spectrometer on NaBr plates, either neat or as evaporated films. Nuclear magnetic resonance spectra were recorded using Varian Unity 500 (500 MHz), Varian INOVA 400 (400 MHz) and Varian Unity 300 (300 MHz) spectrometers at ca. 25°C unless otherwise stated. Coupling constants ( J) are given in hertz (Hz) and chemical shifts are relative to tetramethylsilane. Residual non-deuteriated solvent was used as the internal standard.
Benzyl (N-tert-butoxycarbonyl-L-alaninyl)-D-leucinate (33). Triethylamine (2.98 mL, 21.34 mmol) was added to D-leucine benzyl ester 32 as its toluene p-sulfonate (2.00 g, 5.08 mmol) in DCM (80 mL) and the reaction mixture was stirred at rt for 20 min. Boc-L-alanine (1.05 g, 5.59 mmol), EDC·HCl (1.17 g, 6.10 equiv.) and HOBt (0.69 g, 5.08 mmol) were added and the reaction mixture was stirred at rt for 16 h. DCM (20 mL) was added and the solution was washed with saturated aqueous NH 4 Cl (40 mL), H 2 O (40 mL) and brine (40 mL). The organic extracts were dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (3 : 1 light petroleum : EtOAc) gave the title compound 33 as a pale yellow oil (1.70 g, 85%), [α] D −23.6 (c 1.25, CHCl 3 ) (found: M + + Na, 415.2192. C 21 H 32 N 2 O 5 Na requires M, 415.2209); ν max /cm −1 3308, 2959, 1715, 1661, 1499, 1455, 1366, 1247, 1167 1, 21.8, 22.8, 24.8, 28.2, 41.3, 50.0, 50.7, 67.0, 128.2, 128.3, 128.5, 135.3, 172.4 and 172.6 ; m/z (ES + ) 393.2 (M + + 1, 45%), 337.2 (50) and 127.9 (100).
(N-tert-Butoxycarbonyl-L-alaninyl)-D-leucine (34). A suspension of the benzyl ester 33 (1.70 g, 4.40 mmol) and Pd/C (10%, 0.17 g, 10 wt%) in EtOAc (40 mL) was stirred under H 2 rt for 5, 21.2, 22.9, 24.3, 28.2, 40.2, 49.7, 50.0, 78.0, 154.9, 172.6 3305, 2956, 1652, 1516, 1451, 1366, 1252, 1166, 1103, 839, 779 1, 19.6, 21.9, 23.2, 24.0, 24.8, 25.8, 28.3, 33.0, 39.5, 48.5, 49.6, 50.8, 60.6, 60.9, 61.5, 65.9, 67.1, 69.4, 80.2, 118.8, 131.6, 156.1, 168.3, 169.7, 173.5, 174.5 and 202.6 ; m/z (ES + ) 780.6 (M + + 23, 80%) and 758 (M + + 1, 100) . (22) . Copper(II) chloride (0.11 g, 0.08 mmol) and EDC (0.05 mL, 0.29 mmol) were added to the pentapeptide 35 (0.10 g, 0.13 mmol) in toluene (5 mL) and the reaction mixture was heated at 80°C for 2.5 h before being allowed to cool to rt. Water (10 mL) and EtOAc (20 mL) were added and the organic layer was washed with saturated aqueous NaHCO 3 (10 mL), water (10 mL) and brine (10 mL), then dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (6 : 1 light petroleum : EtOAc) gave the title compound 22 as a viscous yellow oil (51 mg, 53%) containing traces of its 3292, 2955, 2931, 1647, 1511, 1389, 1366, 1166, 1152, 1105, 838, 779 and (2), 14.2, 16.0, 18.1, 21.9, 23.2, 24.1, 24.7, 25.7, 28.2, 32.9, 39.9, 48.0, 49.0, 50.1, 61.3, 61.5, 66.1, 69.0, 80.0, 118.9, 126.4, 129.9, 131.6, 156.7, 164.5, 167.6, 172.4, 174.1 and 203.4 ; m/z (ES + ) 762.7 (M + + 23, 75%), 757.7 (100) and 740.6 (M + + 1, 60).
Prop (36). Triethylamine (34 µL, 0.25 mmol, 1.90 equiv.) and then mesyl chloride (14 µL, 0.18 mmol) were added to the pentapeptide 35 (0.10 g, 0.13 mmol) in DCM (1.20 mL) at 0°C and the reaction mixture was stirred at rt for 30 min. Saturated aqueous NH 4 Cl (10 mL) was added and the mixture was extracted with EtOAc (2 × 10 mL). The organic extracts were washed with water (10 mL) and brine (10 mL 13.9, 15.5, 18.1, 21.9, 23.3, 24.0, 24.8, 25.7, 28.2, 33.0, 39.8, 48.3, 48.7, 50.5, 61.7, 62.3, 66.1, 69.2, 80.0, 118.5, 126.8, 131.7, 135.6, 156.9, 164.8, 166.9, 172.8, 174.4 and 203.4 .
Prop-2-enyl (2S)-2,3-dihydroxypropanoate (44). 17 Concentrated aqueous HCl (8.1 mL) was added to L-serine (4.20 g, 39.97 mmol) in water (190 mL) and the solution cooled to 0°C. An aqueous solution of sodium nitrite (5.53 g, 80.14 mmol, 100 mL) was slowly added at 0°C and the reac- tion mixture was stirred at rt for 24 h. After concentration under reduced pressure, THF (150 mL) was added and the mixture was filtered. The residue was washed with THF (2 × 20 ml) and the organic solution and washings concentrated under reduced pressure. More THF was added and the solution concentrated under reduced pressure. This was repeated five times (with care not to leave the concentrated dihydroxyacid too long at rt to avoid polymerisation) to give (2S)-2,3-dihydroxypropanoic acid as a colourless oil, used directly in the next step (found: [M − H] − , 105.0192. C 3 H 5 O 4 requires M, 105.0193); ν max /cm −1 3318, 3039, 2920, 1614, 1588, 1490, 1462, 1333, 1265, 1245, 1152, 926, 852, 772 0, 66.5, 71.7, 119.1, 131.2 and 172.7 ; m/z (ES + ) 169.0 (M + + 23, 100%).
Prop-2-enyl (2S)-3-hydroxy-2-(2,2,2-trichloroethoxy-carbonyloxy)propanoate (45) . A solution of the propenyl glycerate 44 (100 mg, 0.68 mmol), tert-butyldimethylsilyl chloride (144 mg, 0.96 mmol) and imidazole (70 mg, 1.0 mmol) in THF (3 mL) was stirred at rt for 17 h. The reaction mixture was diluted with ether, washed with saturated aqueous NH 4 Cl and brine, dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (10 : 1 light petroleum : EtOAc) gave prop-2-enyl (2S)-2-hydroxy-3-tert-butyldimethylsilyloxypropanoate 17 6, −5.5, 18.2, 25.7, 65.0, 66.0, 71.9, 118.8, 131.5 and 172.4 ; m/z (ES + ) 283.2 (M + + 23, 100%) and 261.2 (M + + 1, 95) . Minor amounts of the less polar bis-silylated product and unchanged starting material were also obtained.
A solution of the monosilylated ester (768 mg, 02.95 mmol), 2,2,2-trichloroethoxy chloroformate (496 mL), DMAP (188 mg) and pyridine (0.5 mL) in DCM (25 mL) was stirred at rt for 17 h. Ether was added and the mixture was washed with aqueous hydrogen chloride (1 M (2 H, m, m, CO 2 CH 2 ), 4.78 and 4.84 (each 1 H, d, J 12.5 , Cl 3 CCHH), 5.13 (1 H, m, 5.27 (1 H, d, J 10.5, CHvCHH), 5.35 (1 H, d, J 17.2, CHvCHH) and 5.90 (1 H, m, CHvCH 2 ) ; δ C (100 MHz, CDCl 3 ) −5.5 (2), 18.2, 25.7, 62.5, 66.2, 77.6, 94.2, 119.0, 131.2, 153.6 and 166.9. Copper(II) chloride (12 mg) was added to the fully protected glycerate (370 mg, 0.88 mmol) in water (0.5 mL) and acetone (8 mL) and the reaction mixture stirred at 57°C for 17 h then cooled to rt. After dilution with DCM and filtration through sand, concentration of the filtrate under reduced pressure gave the title compound 45 (238 mg, 87%), R f = 0. (1 H, d, J 10.5, CHvCHH), 5.33 (1 H, d, J 17.5, CHvCHH) and 5.90 (1 H, m, CHvCH 2 ) ; δ C (100 MHz, CDCl 3 ) 62. 0, 66.5, 69.4, 77.2, 94.0, 119.2, 131.0, 153.3 and 166.8 The sample of the monoprotected glycerate 45 contained minor tert-butyldimethylsilyl containing residues. However attempts to purify it by chromatography (5 : 1 to 1 : 1 light petroleum : EtOAc) gave a mixture of the Troc-protected glycerate 45 together with the carbonate 46; δ H (400 MHz, CDCl 3 ) carbonate 46 4.56 (1 H, dd, J 9.0, 5.0, 3-H), 4.69 (1 H, t, J 9.0, 3-H′), 4.73-4.80 (2 H, m, CO 2 CH 2 ), 5.11 (1 H, dd, J 9.0, 5.0, 5.34 (1 H, d, J 10.5, CHvCHH), 5.39 (1 H, d, J 17.3, CHvCHH) and 4.94 (1 H, m, CHvCH 2 ) .
Prop-2-enyl (2S)-2-hydroxy-3-(N-methyl-N-tert-butoxycarbonyl-L-valinyloxy)propanoate (48), prop-2-enyl (2S)-3-hydroxy-2-(N-methyl-N-tert-butoxycarbonyl-L-valinyloxy)propanoate (49) and prop-2-enyl (2S)-2,3-bis-(N-methyl-N-tert-butoxycarbonyl-Lvalinyloxy)propanoate (50). Dicyclohexyl carbodi-imide (1.18 g, 5. 62 mmol) in DCM (10.5 mL) was added to the N-methyl-Ntert-butoxycarbonylvaline (47) 18 (1.0 g, 4. 32 mmol), 2,3-dihydroxypropanoate 44 (0.98 g, 6.70 mmol) and DMAP (282 mg, 2.31 mmol) in dry DCM (100 mL) dropwise at 0°C and the solution stirred for 2 h at 0°C and for 2 h at rt. Ether (50 mL) was added and the mixture filtered. After washing the precipitate with ether (2 × 5 mL) and concentration of the filtrate and washings under reduced pressure, chromatography of the residue (1 : 3 EtOAc : light petroleum) gave a minor product provisionally identified as the title compound 50 (248 mg, 10%) as a colourless oil, 1 CDCl 3 ) 18. 9, 19.6, 19.9, 27.7, 28.3, 30.6, 62.1, 62.3, 63.1, 64.9, 66.8, 73.9, 74.1, 77.1, 80.1, 80.4, 93.9, 94.0, 119.5, 130.8, 153.2, 155.3, 156.1, 165.7, 165.8, 170.3 and 170.9; m/ −1 2963, 1741, 1452, 1382, 1247, 1203, 1156, 1049, 820, 780 4, 19.1, 31.3, 35.1, 61.8, 66.7, 69.1, 74.1, 77.1, 93.9, 119.5, 130.8, 153.2, 165.9 and 174.2 Prop-2-enyl (2S)-3-[(N-tert-butyloxycarbonyl-L-threoninyl)-N-methyl-L-valinyloxy]-2-(2,2,2-trichloroethoxycarbonyloxy)propanoate (53). HATU (136 mg, 0.36 mmol) was added to Boc-Lthreonine (135 mg, 0.612 mmol) in DMF : DCM (1 : 1, 3 mL) and the solution stirred at 0°C for 5 min. The valinyl ester 52 (294 mg, 0.67 mmol) in DCM (1.5 mL) was added followed by N-methylmorpholine (0.337 mL, 3.06 mmol) and the mixture was stirred at rt for 3.5 d then concentrated under reduced pressure. EtOAc (10 mL) was added and the solution washed with saturated aqueous NH 4 Cl with the aqueous washing reextracted with EtOAc (10 mL). The organic extracts were washed with brine (10 mL), dried (MgSO 4 and concentrated under reduced pressure. Chromatography of the residue (1 : 1 EtOAc : light petroleum) gave the title compound 53 (332 mg, 85%) as a white foam, R f = 0.75 (1 : 1 EtOAc : light petroleum), [α] 23 D −85 (c 1.0, CHCl 3 ) (found: M + + Na, 657.1351. C 24 H 37 N 2 O 11 Cl 3 Na requires M, 657.1360); ν max /cm −1 3401, 2974, 1752, 1709, 1635, 1491, 1391, 1248, 1172, 1136, 1090, 1050, 1009, 822, 781 (1 H, dd, J 12.5, 4.7, 3-H), 4.58 (1 H, dd, J 12.5, 2.8, 3-H′) 3, 19.5, 19.7, 26.8, 28.1, 31.5, 56.5, 61.0, 62.4, 66.0, 66.5, 73.9, 76.4, 78.1, 94.4, 118.5, 131.6, Paper Organic & Biomolecular Chemistry Prop-2-enyl (2S)-3-[(N-tert-butyloxycarbonyl-L-prolinyl)-Lthreoninyl-N-methyl-L-valinyloxy]-2-(2,2,2-trichloroethoxycarbonyloxy)propanoate (54). Hydrogen chloride in dioxane (4 M, 5.54 mL) was added to the dipeptide ester 53 (260 mg, 0.41 mmol) and the mixture stirred at 0°C for 4 h then concentrated under reduced pressure to provide the hydrochloride salt of the deprotected dipeptide (237 mg) as a yellow oil. N-Methylmorpholine (0.22 mL, 2.04 mmol) and isobutyl chloroformate (0.088 mL, 0.653 mmol) were added to Bocproline (132 mg, 0.612 mmol) in THF (2 mL) at −20°C and the mixture was stirred for 20 min at −20°C. The deprotected dipeptide in THF (2 mL) was added and the mixture was stirred at rt for 15 h then concentrated under reduced pressure. The residue was taken up in EtOAc (10 mL 2, 19.1, 19.3, 22.8, 26.5, 27.8, 31.3, 46.3, 54.2, 59.1, 61.2, 62.0, 65.7, 66.5, 73.8, 76.3, 78.4, 94.2, 118.2, 131.3, 152.2, 153.3, 165.5, 169.3, 171.2 and 171.8. (2S)-3-[(N-tert-Butyloxycarbonyl-L-threoninyl-N-methyl-L-valinyloxy]-2-(2,2,2-trichloroethoxycarbonyloxy)propanoic acid (55). A mixture of the allyl ester 53 (80 mg, 0.13 mmol), phenylsilane (28 μL, 0.25 mmol) and Pd(PPh 3 ) 4 (16 mg, 0.013 mmol) in DCM (7 mL) was stirred at rt for 1.5 h and then concentrated to leave brownish oil. Chromatography (8 : 1 : 1 DCM : MeOH : AcOH) gave a residue that was taken up in EtOAc and chloroform. The solution was concentrated under reduced pressure to leave the title compound 55 (53 mg, 71%) containing a few minor impurities as a pale, yellow foam, R f = 0. 4, 19.0, 19.8, 26.9, 28.2, 31.2, 54.3, 62.2, 63.0, 67.3, 73.8, 80.4, 93.9, 153.2, 156.4, 168.9, 169.6 and 173 5.15 and 5.18 (each 1 H, d, J 12.5, PhHCH), m, ArH) and 7.69 (1 H, br. d, J 7.5, NH) . Isobutyl chloroformate (7 μL, 0.05 mmol) and NMM (16.5 μL, 0.15 mmol) were added to the acid 55 (27 mg, 0.045 mmol) in THF (1 mL) at −15°C and the solution stirred for 10 min. The aminodipeptide 60 (11 mg, 0.04 mmol) was added and the mixture stirred at −20°C to rt for 16 h. The solution was diluted using EtOAc, filtered through Celite and concentrated under reduced pressure. Chromatography gave the coupled product 56 (28 mg) that contained several impurities; δ H (400 MHz, CDCl 3 ) 0.93 (6 H, d, J 6.5, (0.46 mL, 5.72 mmol) were added to the mono-Troc-protected peptide 53 (90 mg, 0.14 mmol) in DCM (9 mL) at 0°C and the reaction mixture was stirred at 0°C for 1 h. Water (15 mL) was added, the mixture was extracted with EtOAc (2 × 15 mL), and the organic extracts were dried (MgSO 4 ) then concentrated under reduced pressure. Chromatography (9 : 1 to 2 : 1 light petroleum : EtOAc) gave the title compound 57 as a pale yellow oil (90 mg, 80%), R f = 0.5 (1 H, dd, J 10.5, m, CO 2 CH 2 , m, 2 × CH 2 CCl 3 , threo 3-H), 4.93 (1 H, d, J 10.5, 5.16 (1 H, m, m, CHvCH 2 , NH) and 5.91 (1 H, ddt, J 17.0, 10.5, 6.0, CHvCH 2 ) ; δ C (125 MHz, CDCl 3 ) 16.7, 18.7, 19.7, 27.3, 28.2, 31.7, 53.9, 61.8, 62.4, 66.8, 74.1, 75.0, 76.8, 77.2, 80.2, 94.0, 94.4, 119.6, 130.8, 153.2, 153.6, 155.6, 165.8, 169.7 and 170.6 ; m/z (ES + ) 833 (M + + 23, 100%).
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Org. Biomol. Chem., 2018, 00, 1-26 | 15 -valinyloxy}-2-(2,2,2-trichloroethoxycarbonyloxy) propanoic acid (58). The catalyst Pd(PPh 3 ) 4 (10 mg, 8.9 µmol, 10 mol%) and phenylsilane (22 µL, 0.18 mmol) were added to the allyl ester 57 (70 mg, 0.09 mmol) in DCM (6 mL) and the reaction mixture stirred in the absence of light for 1 h. After concentration under reduced pressure, chromatography of the residue (4 : 1 to 1 : 1 light petroleum : EtOAc) gave the title compound 58 as a yellow viscous oil (38 mg, 55%), R f = 0.50 (1 : 1 light petroleum : EtOAc), [α] 28 D −159 (c 0.99 in CHCl 3 ) (found: M + − H, 767.0101. C 24 H 33 N 2 O 13 Cl 6 requires M, 767.0108); ν max /cm −1 2968 , 1755 , 1248 , 1169 , 1048 δ H (400 MHz, DMSO-d 6 ) 0.73 and 0.95 (each 3 H, d, J 7.0, either val 3-CH 3 or val 4-H 3 ), 1.25 (3 H, d, J 6.5, threo 4-H 3 ), 1.35 [9 H, s, OC(CH 3 
], 2.15 (1 H, m, val 3-H) , 3.01 (3 H, s, NCH 3 ), 4.49 (1 H, m, m, 4.81 (1 H, d, J 10.5, m, 2 × CH 2 CCl 3 , threo 3-H), 5.32 (1 H, m, d, J 8.0, NH) ; δ C (100 MHz, DMSO-d 6 ) 16.3, 18.3, 19.8, 26.6, 28.0, 31.2, 53.5, 60.9, 62.7, 74.0, 75.2, 75.9, 76.3, 78.5, 94.5, 94.9, 152.7, 155.4, 167.5, 169.5 and 170.5 (3 H, d, J 6.5, val 4-H 3 ), 0.90-0.98 (9 H, m, , leu 4-CH 3 , leu 5-H 3 ), 1.35-1.66 (9 H, m, ala 3-H 3 , threo 4-H 3 , leu 4-H, leu 3-H 2 ), 1.41 [9 H, s, OC(CH 3 ) 3 ], 2.29 (1 H, m, val 3-H) , 3.07 (3 H, s, NCH 3 ), 4.49 (1 H, m, m, m, CH 2 CCl 3 ), 5. 10-5.18 (3 H, m , threo 3-H, PhCH 2 ), 5.50 (1 H, d, J 9.5 , NH), 6.62 (1 H, d, J 8.0, NH), 6.69 (1 H, d, J 7.5, m, ArH) ; δ C (100 MHz, CDCl 3 ) 16.9, 17.4, 18.2, 19.6, 21.9, 22.8, 24.8, 25.6, 28.2, 30.9, 41.4, 48.8, 50.8, 53.3, 62.6, 67.0, 74.7, 80.3, 94.3, 128.2, 128.4, 128.6, 135.3, 153.7, 155.7, 169.5, 170.7, 171.4 and 172.5 ; m/z (ES + ) 833.6 (100%) and 803.4 (M + + 23, 70).
Prop-2-enyl (2S)-3-[(N-tert-butyloxycarbonyl-L-threoninyl)-Nmethyl-L-valinyloxy]-2-hydroxypropanoate (64). Activated zinc (92 mg) was added to the Troc-protected glycerate 53 (68 mg, 0.11 mmol) in a mixture of HOAc (0.5 mL) and Et 2 O (0.5 mL) cooled in an ice bath and the suspension was stirred at rt for 2 h until the reaction was complete (TLC, 1 : 2 EtOAc : light petroleum). Ether (3 mL) was added, the mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was taken up in EtOAc (3 mL) and concentrated under reduced pressure three times to remove the acetic acid. This process was repeated using CHCl 3 and final concentration under reduced pressure gave the title compound 64 (44 mg, 96%) as a white foam (found: M + + 1, 461.2472. C 21 H 37 N 2 O 9 requires M, 461.2494); ν max /cm −1 3365, 2975 , 1744 , 1709 , 1598 , 1501 , 1455 , 1393 , 1369 , 1251 , 1164 , 1134 , 1063 , 1010 δ H (500 MHz, 20°C, DMSO-d 6 ) 0.74 and 0.92 (each 3 H, d, J 6.6, either val 3-CH 3 or val 4-H 3 ), 1.01 (3 H, d, J 6.3, threo 4-H 3 ), 1.35 [9 H, s, OC(CH 3 ) 3 ], 2.13 (1 H, m, val 3-H) , 3.02 (3 H, s, NCH 3 ), 3.76 (1 H, m, 4.19 (1 H, dd, J 11.3, 5.3, m, 4.60 (2 H, m, CO 2 CH 2 ), 4.69 (1 H, d, J 6.0, threo OH), 4.74 (1 H, d, J 10.4, 5.23 (1 H, dq, J 11.9, 1.5, CHvCHH), 5.32 (1 H, dq, J 17.2, 1.5, CHvCHH), 5.84 (1 H, d, J 6.0, 5.90 (1 H, m, CHvCH 2 ) and 6.72 (1 H, d, J 7.8, NH) −1 2970, 1744, 1712, 1652, 1500, 1370, 1234, 1173, 1106, 1061 (1 H, dd, J 12.1, 5.5, 3-H), 4.60-4.67 (3 H, m, 3- H′, CO 2 CH 2 ), 4.68 (1 H, m, 4.85 (1 H, d, J 10.4, m, CHvCHH, m, CHvCHH, 5.39 (1 H, d, J 9.3, NH) and 5.88 (1 H, m, CHvCH 2 ) ; δ C (100 MHz, CDCl 3 ) 16.8, 18.7, 19.5, 20.4, 20.9, 27.3, 28.2, 31.5, 54.0, 61.7, 62.7, 66.3, 69.2, 70.2, 79.9, 119.1, 131.1, 155.7, 166.7, 169.7, 169.8, 170.1 and 170.6; m/ 67) . Following the procedure outlined for the preparation of the acid 58, the allyl ester 65 (40 mg, 0.073 mmol), phenylsilane (16 mg, 0.15 mmol) and Pd(PPh 3 ) 4 (8 mg, 0.007 mmol) in DCM (5.8 mL) with stirring in the dark, after concentration under reduced pressure, gave the acid 66. This acid (15 mg, 0.03 mmol) was coupled with the amine 60 (12 mg, 0.042 mmol) using PyBOP (20 mg, 0.047 mmol) and NMM (0.015 mL, 0.15 mmol) in DCM (8 mL) following the procedure outlined for the synthesis of the peptide 59, to give the title compound 67 (24 mg, 85%) as a pale yellow oil (found: M + + Na, 801.3872. C 38 16.4, 18.4, 18.5, 19.7, 20.6, 21.0, 21.1, 22.7, 24.2, 26.7, 28.0, 31.4, 48.1, 50.2, 53.6, 61.1, 63.3, 66.0, 69.7, 71.1, 78.4, 127.8, 128.1, 128.4, 135.9, 155.5, 165.6, 169.6(2), 169.7, 170.8, 171.9 Methyl L-prolinate (10 mg, 0.08 mmol), PyBOP (47 mg, 0.09 mmol) and N-methylmorpholine (0.02 mL, 0.18 mmol) were added to the acid derived from the pentapeptide 75 (65 mg, 0.08 mmol) in DCM (1.10 mL) at 0°C and the reaction mixture was stirred at rt for 4.5 h. DCM (10 mL) was added and the solution washed with saturated aqueous NH 4 Cl (10 mL), water (10 mL) and brine (10 mL −1 3281, 2955, 2929, 1746, 1678, 1645, 1628, 1532, 1502, 1436, 1390, 1366, 1329, 1254, 1169, 1106, 839 16-8.18 (2 H, m, 2 × NH) and 8.87 (1 H, d, J 7.5, NH) ; δ C (100 MHz, CDCl 3 ) −5. 3, 11.9, 14.2, 18.1, 21.2, 22.6, 23.5, 24.1, 24.8, 25.7, 28.2, 30.5, 32.9, 39.6, 45.8, 48.1(2) , 50. 6, 52.1, 61.6, 62.3, 62.4, 69.4, 79.3, 119.7, 130.4, 158.2, 167.0, 168.6, 173.1, 173.7, 175.2 and 203.6 ; m/z (ES + ) 811.5 (M + + 1, 100%).
tert-Butyl hydroperoxide in decane (5.5 M, 0.09 mL) was added to the peptide 80 (50 mg, 0.05 mmol) in DCM (0.5 mL) at 0°C and the reaction mixture stirred at 0°C for 5 min then at rt for 3 h. Saturated aqueous Na 2 S 2 O 3 (2 mL) was added and the mixture was stirred at rt for 30 min then extracted with EtOAc (3 × 5 mL (20 mg, 0.14 mmol) , PyBOP (80 mg, 0.15 mmol) and N-methylmorpholine (0.03 mL, 0.31 mmol) were added to the 3-phenylselanylbutanoic acid 71 (50 mg, 0.14 mmol) in DCM (2.2 mL) at 0°C and the reaction mixture was stirred at rt for 4 h. DCM (10 mL) was added and the solution washed with saturated aqueous NH 4 Cl (10 mL), water (10 mL) and brine (10 mL 3305, 2975, 1745, 1709, 1645, 1497, 1435, 1391, 1166, 1020 16.8, 24.8, 28.3, 28.9, 42.0, 46.6, 52.3, 54.8, 58.8, 79.9, 128.0, 129.0, 129.4, 135.8, 155.6, 169.1 and 172.2 ; m/z (ES + ) 471.1 (M + + 1, 100%) and 469. 1 (95) .
Methyl N-[(2R,3S)-2-(N-tert-butoxycarbonyl-O-tert-butyldimethylsilyl-L-serinyl)amino-3-phenylselanylbutanoyl]-L-prolinate (78). Trifluoroacetic acid (1.7 mL) was added to the Boc-protected dipeptide 77 (0.87 g, 1.87 mmol) in DCM (6.8 mL) at 0°C and the reaction mixture stirred at rt for 1.5 h. DCM (10 mL) was added and the solution washed with saturated aqueous NaHCO 3 (30 mL), water (15 mL) and brine (15 mL) . The aqueous extracts were re-extracted with DCM (20 mL) and the organic extracts were dried (MgSO 4 ) and concentrated under reduced pressure to give the corresponding amine that was then dissolved in DCM (10 mL) and added to N-Boc-O-TBS-protected L-serine (0.46 g, 2.24 mmol) and HATU (0.68 g, 2.43 mmol) at 0°C. Di-isopropylethylamine (0.81 mL, 4.68 mmol) was added and the reaction mixture stirred at rt for 32 h. DCM (15 mL) was added and the solution was washed with saturated aqueous NH 4 Cl (20 mL), water (20 mL) and brine (20 mL (2.17 g, 25. 86 mmol) and tert-butoxycarbonyl anhydride (5.72 g, 26.19 mmol) in MeOH (34 mL) were added to allo-L-threonine (2 g, 16.79 mmol) in water (34 mL) and the reaction mixture was stirred at rt for 24 h. The reaction mixture was acidified to pH 2 using aqueous HCl (0.5 M) and extracted with EtOAc (3 × 100 mL). The organic extracts were dried (MgSO 4 ) and concentrated under reduced pressure to give the title compound 94 as a colourless oil (3.68 g, ca. 100%), R f = 0.25 (1 : 1 light petroleum : EtOAc), [α] 26 D +12.4 (c 1.0, CHCl 3 ) (found: M + + Na, 242.0989. C 9 H 17 NO 5 Na requires M, 242.0999); ν max /cm −1 3345, 2979, 1691, 1512, 1394, 1368, 1252, 1162 28.2, 59.0, 69.1, 80.9, 156.5 and 173.4 ; m/z (ES − ) 218.0 ([M − 1] − , 40%) and 143.9 (100).
(3S,4S)-3-tert-Butoxycarbonylamino-4-methyloxetan-2-one (95). 30 PyBOP (10.5 g, 20.14 mmol) and Et 3 N (7.0 mL, 50.4 mmol) were added the Boc-L-allothreonine 94 (3.68 g, 16.79 mmol) in dry DCM (245 mL) at 0°C and the reaction mixture was stirred for 1 h at 0°C and at rt for 1 h. Saturated aqueous NH 4 Cl (100 mL) was added and the organic phase was washed with water (100 mL) and brine (100 mL), then dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (2 : 1 light petroleum : EtOAc) gave the title compound 95 as a white semi-solid (3.21 g, 95%), R f = 0.6 (1 : 1 light petroleum : EtOAc), [α] 26 D −45.4 (c 0.9, CHCl 3 ), lit. 30 −81.7 (c, 0.45, MeOH) (found: M + + Na, 224.0885. C 9 H 15 NO 4 Na requires M, 224.0899); ν max /cm −1 3355, 2992, 1825, 1690, 1537, 1367, 1328, 1292, 1254, 1167, 1131, 1022 and 821; δ H (400 MHz, CDCl 3 ) 1.46 [9 H, s, OC(CH 3 ) 3 ], 1.61 (3 H, d, J 6.1, ), 4.58 (1 H, dd, J 7.5, 4.0, 3-H), 4.75 (1 H, m, 4-H) and 5.22 (1 H, br. s, NH) ; δ C (100 MHz, CDCl 3 ) 18. 7, 28.2, 64.3, 76.8, 81.3, 154.4 (2R,3R)-2-tert-Butoxycarbonylamino-3-phenylselanylbutanoic acid (96). 24 Benzeneselenol (7.52 mL, 47.86 mmol) was added dropwise to the oxetanone 95 (3.21 g, 15.95 mmol) in dry, degassed DMF (26 mL) and the reaction mixture was heated to 80°C for 3 h then cooled to rt. Aqueous NaOH (1 M, 36 mL) and water (72 mL) were added and the reaction mixture was extracted with Et 2 O (3 × 90 mL). The aqueous layer was acidified to pH 3 with aqueous HCl (1 M) and washed with EtOAc (3 × 90 mL). The organic extracts were washed with water (2 × 75 mL), dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (3 : 1 to 1 : 1 light petroleum : EtOAc) gave the title compound 96 24 as a pale yellow viscous oil (5.31 g, 93%) , R f = 0.8 (1 : 1 light petroleum : EtOAc), [α] 26 D +45.8 (c 1.0, CHCl 3 ) (found: M + + Na, 382.0515. C 15 H 21 NO 4 SeNa requires M, 382.0533); ν max /cm −1 2978, 2928, 1715, 1477, 1394, 1368, 1251, 1160, 1081, 1022 and 741 ; δ H (400 MHz, CDCl 3 ) 1.47 [9 H, s, OC(CH 3 ) 3 ], 1.52 (3 H, d, J 7.5, 4-H 3 ), 3.83 (1 H, m, 4.57 (1 H, m, 5.35 (1 H, d, J 9.5, NH), m, ArH), m, ArH) and 11.16 (1 H, br. S, OH) ; m/z (ES + ) 398.0 (M + + 39, 75%), 382.0 (M + + 23, 50) and 380.0 (M + + 23, 70).
Methyl N-[(2R,3R)-2-tert-butoxycarbonylamino-3-phenylselanylbutanoyl]-L-prolinate (97). Methyl L-prolinate (2.48 g, 14. 97 mmol), PyBOP (10.02 g, 19.27 mmol) and N-methylmorpholine (4.89 mL, 44.46 mmol) were added to the 3-phenylselanylbutanoic acid 96 (5.31 g, 14. 82 mmol) in dry DCM (180 mL) at 0°C and the reaction mixture was stirred at rt for 19 h then diluted with DCM (227 mL). The solution was washed with saturated aqueous NH 4 Cl (302 mL), water (302 mL) and brine (302 mL), then dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography (1 : 1 light petroleum : EtOAc) of the residue gave the title compound 97 as an off-white foam (6.82 3304, 2976, 1746, 1705, 1639, 1514, 1436, 1366, 1245, 1170, 1012 and 743 ; δ H (500 MHz, CDCl 3 ) 1.42-1.45 [12 H, m, OC(CH 3 24.7, 28.2, 29.0, 42.0, 47.2, 52.0, 56.3, 58.8, 79.7, 127.7, 127.8, 128.8, 135.7, 155.1, 170. Methyl N-[(2R,3R)-2-(N-tert-butoxycarbonyl-O-tert-butyldimethylsilyl-L-serinylamino)-3-phenylselanylbutanoyl]-L-prolinate (98). Trifluoroacetic acid (11 mL) was added to the Boc-protected dipeptide 97 (6.82 g, 14.53 mmol) in dry DCM (52 mL) at 0°C and the solution was stirred at 0°C for 30 min and at rt for 30 min. DCM (173 mL) was added and the solution washed with saturated aqueous NaHCO 3 (260 mL), water (260 mL) and brine (260 mL). The aqueous extracts were extracted with DCM (2 × 175 mL) and the organic extracts were dried (MgSO 4 ) and concentrated under reduced pressure to give the aminodipeptide that was dissolved in DCM (173 mL) and added to N-tert-butoxycarbonyl-O-tert-butyldimethylsilyl-L-serine (5.57 g, 17. 44 mmol) and HATU (7.18 g, 18. 89 mmol) at 0°C. Di-isopropylethylamine (6.33 mL, 36.32 mmol) was added and the reaction mixture was stirred at rt for 16 h. DCM (260 mL) was added and the solution was washed with saturated aqueous NH 4 Cl (346 mL), water (346 mL) and brine (346 mL) then dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue (2 : 1 to 1 : 1 light petroleum : EtOAc) gave the title compound 98 as a yellow oil (6.92 g, 71%), R f = 0.7 (1 : 1 light petroleum : EtOAc), [α] 25 D −38.6 (c 1.0, CHCl 3 ) (found: M + + H, 672.2566. C 30 H 50 N 3 O 7 SeSi requires M, 672.2578); ν max /cm −1 3313, 2954, 2929, 2857, 1790, 1748, 1715, 1640, 1472, 1436, 1365, 1252, 1170, 1111, 837, 779 tion mixture was stirred at rt for 45 min then concentrated under reduced pressure to give the corresponding carboxylic acid. HATU (50 mg, 0.13 mmol) and N-methylmorpholine (70 µL, 0.64 mmol) were added to this acid in DCM (400 µL) at 0°C. The aminodipeptide 60 (35 mg, 0.12 mmol) in DCM (0.4 mL) was added at 0°C and the reaction mixture stirred at rt for 16 h. After concentration under reduced pressure, the residue was dissolved in EtOAc and the solution was washed with saturated aqueous NH 4 Cl, saturated aqueous NaHCO 3 and brine, then dried (MgSO 4 ) and concentrated under reduced pressure. Chromatography of the residue ( 
